Stockholders' Equity Attributable to Parent of Vitro Biopharma, Inc. from 31 Oct 2011 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
Summary
Vitro Biopharma, Inc. quarterly Stockholders' Equity Attributable to Parent in USD history and change rate from 31 Oct 2011 to 31 Oct 2025.
  • Vitro Biopharma, Inc. Stockholders' Equity Attributable to Parent for the quarter ending 31 Oct 2025 was $16,333,667, a 81% decline year-over-year.
Source SEC data
View on sec.gov
Stockholders' Equity Attributable to Parent, Quarterly (USD)
Stockholders' Equity Attributable to Parent, YoY Quarterly Change (%)

Vitro Biopharma, Inc. Quarterly Stockholders' Equity Attributable to Parent (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $16,333,667 -$7,332,694 -81% 31 Oct 2025 10-K 13 Feb 2026 2025 FY
Q2 2025 $12,078,921 -$4,756,926 -65% 31 Jul 2025 10-Q 12 Sep 2025 2025 Q3
Q1 2025 $11,065,453 -$3,509,109 -46% 30 Apr 2025 10-Q 12 Sep 2025 2025 Q3
Q4 2024 $9,909,401 -$5,083,609 -105% 31 Jan 2025 10-Q 12 Sep 2025 2025 Q3
Q3 2024 $9,000,973 -$7,909,883 -725% 31 Oct 2024 10-K 13 Feb 2026 2025 FY
Q2 2024 $7,321,995 -$7,721,531 -1933% 31 Jul 2024 10-Q 12 Sep 2025 2025 Q3
Q1 2024 $7,556,344 -$8,441,384 -954% 30 Apr 2024 10-Q 12 Sep 2025 2025 Q3
Q4 2023 $4,825,792 -$6,732,022 -353% 31 Jan 2024 10-Q 12 Sep 2025 2025 Q3
Q3 2023 $1,091,090 -$3,926,930 -138% 31 Oct 2023 10-K 13 Feb 2026 2025 FY
Q2 2023 $399,536 -$4,479,730 -92% 31 Jul 2023 10-Q 16 Sep 2024 2024 Q3
Q1 2023 $885,040 -$5,461,420 -86% 30 Apr 2023 10-Q 16 Sep 2024 2024 Q3
Q4 2022 $1,906,230 -$1,429,069 -43% 31 Jan 2023 10-Q 16 Sep 2024 2024 Q3
Q3 2022 $2,835,840 -$618,686 -18% 31 Oct 2022 10-K 28 Jan 2025 2024 FY
Q2 2022 $4,879,266 31 Jul 2022 10-Q 28 Aug 2023 2023 Q3
Q1 2022 $6,346,460 30 Apr 2022 10-Q 28 Aug 2023 2023 Q3
Q4 2021 $3,335,299 31 Jan 2022 10-Q 28 Aug 2023 2023 Q3
Q3 2021 $3,454,526 31 Oct 2021 10-K 29 Jan 2024 2023 FY
Q3 2015 $2,381,871 -$221,865 -10% 31 Oct 2015 10-K 22 Sep 2016 2015 FY
Q2 2015 $2,321,693 -$232,321 -11% 31 Jul 2015 10-Q 30 Mar 2016 2015 Q3
Q1 2015 $2,284,269 -$236,804 -12% 30 Apr 2015 10-Q 22 Jan 2016 2015 Q2
Q4 2014 $2,208,876 -$220,489 -11% 31 Jan 2015 10-Q 24 Mar 2015 2015 Q1
Q3 2014 $2,160,006 -$226,527 -12% 31 Oct 2014 10-K 22 Sep 2016 2015 FY
Q2 2014 $2,089,372 -$197,884 -10% 31 Jul 2014 10-Q 22 Sep 2014 2014 Q3
Q1 2014 $2,047,465 -$186,674 -10% 30 Apr 2014 10-Q 19 Jun 2014 2014 Q2
Q4 2013 $1,988,387 -$195,569 -11% 31 Jan 2014 10-Q 17 Mar 2014 2014 Q1
Q3 2013 $1,933,479 -$178,746 -10% 31 Oct 2013 10-K 13 Feb 2015 2014 FY
Q2 2013 $1,891,488 -$172,189 -10% 31 Jul 2013 10-Q 23 Sep 2013 2013 Q3
Q1 2013 $1,860,791 30 Apr 2013 10-Q 18 Jun 2013 2013 Q2
Q4 2012 $1,792,818 31 Jan 2013 10-Q 21 Mar 2013 2013 Q1
Q3 2012 $1,754,733 -$188,472 -12% 31 Oct 2012 10-K 12 Feb 2014 2013 FY
Q2 2012 $1,719,299 31 Jul 2012 10-Q/A 17 Oct 2012 2012 Q3
Q3 2011 $1,566,261 31 Oct 2011 10-K 12 Feb 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.